Novavax (NASDAQ:NVAX) inks an agreement with South Korea’s SK Group subsidiary SK bioscience for the development and supply of the antigen component of COVID-19 vaccine candidate NVX-CoV2373.
The parties have also signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare aimed at working toward broad access of NVX-CoV2373 in South Korea and global markets.
Financial terms remain confidential.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.